Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync
I'm PortAI, I can summarize articles.
Dec 3 (Reuters) - Nexalin Technology Inc:NEXALIN TECHNOLOGY COMPLETES FDA Q-SUBMISSION MEETING FOR GEN-2 SYNC™ NEUROSTIMULATION CONSOLE IN ALZHEIMER’S DISEASE PROGRAMNEXALIN TECHNOLOGY INC - PLANS U.S. PILOT AND PIVOTAL STUDIES FOR GEN-2 SYNCNEXALIN TECHNOLOGY INC - POTENTIAL DE NOVO PATHWAY DISCUSSED FOR NEXALIN’S TECHNOLOGYNEXALIN TECHNOLOGY INC - REVIEWED ENDPOINTS FOR ALZHEIMER’S OUTCOMES INCLUDING COGNITIVE ASSESSMENTS Source text: Further company coverage:
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments